Mariam F. Eskander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mariam F. Eskander has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer F. Tseng
Surgical Outcomes Analysis & Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
16 shared publications Sing Chau Ng
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
13 shared publicationsGyulnara G. Kasumova
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
9 shared publicationsMark P. Callery
Beth Israel Deaconess Medical Center, Department of Surgery, Boston, MA, USA
9 shared publicationsTara S. Kent
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
8 shared publicationsA. James Moser
7 shared publications
Latest Publications
- 19 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 721-729
Social vulnerability and clinical trial enrollment: the next frontier of health equity
Background: Clinical trials drive novel cancer therapies, yet enrollment remains low and unrepresentative of vulnerable groups. Most clinical trial disparities literature examines demographics, excluding social determinants of health. We evaluated the association between social vulnerability and clinical trial enrollment among patients with the 5 leading causes of cancer death and examined how this association varies by race and ethnicity in the United States. Methods: In this retrospective cohort study, the national Vizient Clinical Database was queried for patients with lung, breast, prostate, colorectal or pancreatic cancer from 2022 to 2023. The exposure was the Vizient Vulnerability Index, a novel, healthcare-specific tool assessing census tract–level social vulnerability. The primary outcome was clinical trial enrollment. Multivariable analysis evaluated the association of Vizient Vulnerability Index with clinical trial enrollment, including tests for interaction by race. Results: Of 2 660 566 patients, 36 456 (1.4%) enrolled in a clinical trial. Trial participants were more likely to be young, non-Hispanic White, and privately insured and to have metastases. Enrollment odds were lower for patients living in the most vulnerable census tracts (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.77 to 0.89) and non-Hispanic Black patients (OR = 0.80, 95% CI = 0.75 to 0.83). Vulnerability in education, transportation, and neighborhood resources was associated with decreased enrollment. High social vulnerability disproportionately impacted enrollment for non-Hispanic Black patients (OR = 0.48, 95% CI = 0.41 to 0.62) compared with non-Hispanic White patients (OR = 0.82, 95% CI = 0.73 to 0.92; P < .0001 for interaction). Conclusions: Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among non-Hispanic Black patients. Focused interventions targeting education, transportation, and neighborhood resources may increase equity.
- 19 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 721-729
Social vulnerability and clinical trial enrollment: the next frontier of health equity
Background: Clinical trials drive novel cancer therapies, yet enrollment remains low and unrepresentative of vulnerable groups. Most clinical trial disparities literature examines demographics, excluding social determinants of health. We evaluated the association between social vulnerability and clinical trial enrollment among patients with the 5 leading causes of cancer death and examined how this association varies by race and ethnicity in the United States. Methods: In this retrospective cohort study, the national Vizient Clinical Database was queried for patients with lung, breast, prostate, colorectal or pancreatic cancer from 2022 to 2023. The exposure was the Vizient Vulnerability Index, a novel, healthcare-specific tool assessing census tract–level social vulnerability. The primary outcome was clinical trial enrollment. Multivariable analysis evaluated the association of Vizient Vulnerability Index with clinical trial enrollment, including tests for interaction by race. Results: Of 2 660 566 patients, 36 456 (1.4%) enrolled in a clinical trial. Trial participants were more likely to be young, non-Hispanic White, and privately insured and to have metastases. Enrollment odds were lower for patients living in the most vulnerable census tracts (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.77 to 0.89) and non-Hispanic Black patients (OR = 0.80, 95% CI = 0.75 to 0.83). Vulnerability in education, transportation, and neighborhood resources was associated with decreased enrollment. High social vulnerability disproportionately impacted enrollment for non-Hispanic Black patients (OR = 0.48, 95% CI = 0.41 to 0.62) compared with non-Hispanic White patients (OR = 0.82, 95% CI = 0.73 to 0.92; P < .0001 for interaction). Conclusions: Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among non-Hispanic Black patients. Focused interventions targeting education, transportation, and neighborhood resources may increase equity.
- Open Access
- 12 August 2021
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (1) , 111-119
Hormone receptor-positive breast cancer and black race: does sex matter?
Purpose Black breast cancer patients have worse clinical outcomes than their White counterparts. There are few studies comparing clinical outcomes between Black male breast cancer (MBC) and female breast cancer (FBC) patients. The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC. Methods The National Cancer Database was queried for all Black MBC and FBC patients, ages 18–90, with hormone receptor-positive breast cancer diagnosed between 2010 and 2016. Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer. Sociodemographic and clinical variables were compared between MBC and FBC patients on bivariable analysis. After propensity score matching, overall survival was evaluated using the log-rank test and Cox proportional hazards. Results Compared to FBC patients, MBC patients had higher rates of metastatic disease (stage 4, MBC 4.4% vs. FBC 2.6%, p < 0.001), larger tumors (tumor size < 2 cm, MBC 32.1 vs. FBC 49.1%, p < 0.001) and a higher percentage of poorly differentiated tumors (grade 3, MBC 28.5% vs. FBC 21.4%, p < 0.001). MBC patients had lower rates of hormone therapy (MBC 66.4% vs. FBC 80.7%, p < 0.001) and neoadjuvant chemotherapy (MBC 5.8% vs. FBC 7.5%, p = 0.05) than FBC. On propensity score matched analysis, Black MBC patients had a higher overall mortality (p25 of 60 months vs. 74 months) compared to FBC patients (p = 0.0260). Conclusion Among hormone receptor-positive Black MBC and FBC patients, there are sex-based disparities in stage, hormone therapy use and overall survival.
- 12 August 2021
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (1) , 111-119
Open AccessHormone receptor-positive breast cancer and black race: does sex matter?
Purpose Black breast cancer patients have worse clinical outcomes than their White counterparts. There are few studies comparing clinical outcomes between Black male breast cancer (MBC) and female breast cancer (FBC) patients. The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC. Methods The National Cancer Database was queried for all Black MBC and FBC patients, ages 18–90, with hormone receptor-positive breast cancer diagnosed between 2010 and 2016. Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer. Sociodemographic and clinical variables were compared between MBC and FBC patients on bivariable analysis. After propensity score matching, overall survival was evaluated using the log-rank test and Cox proportional hazards. Results Compared to FBC patients, MBC patients had higher rates of metastatic disease (stage 4, MBC 4.4% vs. FBC 2.6%, p < 0.001), larger tumors (tumor size < 2 cm, MBC 32.1 vs. FBC 49.1%, p < 0.001) and a higher percentage of poorly differentiated tumors (grade 3, MBC 28.5% vs. FBC 21.4%, p < 0.001). MBC patients had lower rates of hormone therapy (MBC 66.4% vs. FBC 80.7%, p < 0.001) and neoadjuvant chemotherapy (MBC 5.8% vs. FBC 7.5%, p = 0.05) than FBC. On propensity score matched analysis, Black MBC patients had a higher overall mortality (p25 of 60 months vs. 74 months) compared to FBC patients (p = 0.0260). Conclusion Among hormone receptor-positive Black MBC and FBC patients, there are sex-based disparities in stage, hormone therapy use and overall survival.
- 1 August 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 252, 281-284
Overcoming a Hostile Work and Learning Environment in Academic Surgery—Tools for Change at Every Level
- 1 August 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 252, 281-284
Overcoming a Hostile Work and Learning Environment in Academic Surgery—Tools for Change at Every Level
- 1 December 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 266 (6) , 1055-1061
Nationwide Evaluation of Patient Selection for Minimally Invasive Distal Pancreatectomy Using American College of Surgeons’ National Quality Improvement Program
To assess current nationwide case selection factors for minimally invasive distal pancreatectomy (MIDP) and identify actual risk factors for adverse outcomes compared with open distal pancreatectomy (ODP). Patient selection criteria that predict outcomes after MIDP remain unknown. As a result, widespread adoption of this surgical technique may have been delayed and its potential benefits possibly under-exploited. Retrospective cohort study of elective ODP and MIDP performed at 106 centers in 2014, using the pancreas-targeted American College of Surgeons’ National Quality Improvement Program (ACS-NSQIP) database. Exclusion criteria were neoadjuvant treatment or pancreatitis as only diagnosis. Primary outcome includes a composite major morbidity metric, reflecting adverse events including mortality and reoperation. Multivariable modeling was used to detect current selection factors and to identify actual risk factors of composite major morbidity. A total of 928 patients underwent ODP (n = 472) or MIDP (n = 456) using a laparoscopic or robot-assisted approach, 24% for pancreatic ductal adenocarcinoma (PDAC). Current selection factors for MIDP were benign disease (odds ratio: OR: 1.56, CI: 1.10–2.21) and body mass index (BMI) 30–40 (OR: 1.41, CI: 1.04–1.91). Current selection factors for ODP were PDAC (OR: 0.45, CI: 0.31–0.64), benign tumor size >5 centimeters (OR: 0.40, CI: 0.23–0.67), and multivisceral procedures (OR: 0.39, CI: 0.26–0.59). Risk factors for composite major morbidity did not differ between ODP and MIDP. A trend was observed between MIDP and a lower risk of composite major morbidity compared with ODP (OR: 0.43, CI: 0.17–1.07). Current selection factors for ODP or MIDP (benign disease, tumor size, and BMI) do not mitigate the risk of major morbidity. We found no evidence that MIDP should be avoided based on tumor etiology or size, BMI, or patient physical status.
- 1 December 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 266 (6) , 1055-1061
Nationwide Evaluation of Patient Selection for Minimally Invasive Distal Pancreatectomy Using American College of Surgeons’ National Quality Improvement Program
To assess current nationwide case selection factors for minimally invasive distal pancreatectomy (MIDP) and identify actual risk factors for adverse outcomes compared with open distal pancreatectomy (ODP). Patient selection criteria that predict outcomes after MIDP remain unknown. As a result, widespread adoption of this surgical technique may have been delayed and its potential benefits possibly under-exploited. Retrospective cohort study of elective ODP and MIDP performed at 106 centers in 2014, using the pancreas-targeted American College of Surgeons’ National Quality Improvement Program (ACS-NSQIP) database. Exclusion criteria were neoadjuvant treatment or pancreatitis as only diagnosis. Primary outcome includes a composite major morbidity metric, reflecting adverse events including mortality and reoperation. Multivariable modeling was used to detect current selection factors and to identify actual risk factors of composite major morbidity. A total of 928 patients underwent ODP (n = 472) or MIDP (n = 456) using a laparoscopic or robot-assisted approach, 24% for pancreatic ductal adenocarcinoma (PDAC). Current selection factors for MIDP were benign disease (odds ratio: OR: 1.56, CI: 1.10–2.21) and body mass index (BMI) 30–40 (OR: 1.41, CI: 1.04–1.91). Current selection factors for ODP were PDAC (OR: 0.45, CI: 0.31–0.64), benign tumor size >5 centimeters (OR: 0.40, CI: 0.23–0.67), and multivisceral procedures (OR: 0.39, CI: 0.26–0.59). Risk factors for composite major morbidity did not differ between ODP and MIDP. A trend was observed between MIDP and a lower risk of composite major morbidity compared with ODP (OR: 0.43, CI: 0.17–1.07). Current selection factors for ODP or MIDP (benign disease, tumor size, and BMI) do not mitigate the risk of major morbidity. We found no evidence that MIDP should be avoided based on tumor etiology or size, BMI, or patient physical status.
- 4 October 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 22 (2) , 214-225
Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study
- 4 October 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 22 (2) , 214-225
Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
BACKGROUND: The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer.METHODS: The National Cancer Data Base was queried for unresected patients who received chemotherapy for nonmetastatic pancreatic adenocarcinoma between 2004 and 2012. Four treatment groups were identified: chemotherapy alone, chemotherapy combined with external‐beam radiotherapy (EBRT), chemotherapy combined with intensity‐modulated radiotherapy (IMRT), and chemotherapy combined with SBRT. Propensity score models predicting the odds of receiving SBRT were created to control for potential selection bias, and patients were matched by propensity scores. The survival analysis was performed with the Kaplan‐Meier method.RESULTS: A total of 14,331 patients met the inclusion criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy along with EBRT, IMRT, and SBRT, respectively. The unadjusted median survival before matching was 9.9, 10.9, 12.0, and 13.9 months for patients treated with chemotherapy, EBRT, IMRT, and SBRT, respectively. In separate matched analyses, SBRT remained superior to chemotherapy alone (log‐rank P < .0001) and EBRT (log‐rank P = .0180). After matching, survival did not differ between patients receiving IMRT and patients receiving SBRT (log‐rank P = .0492).CONCLUSIONS: SBRT is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional EBRT. These results support the idea that SBRT is a promising treatment approach for patients with unresected pancreatic cancer. Cancer 2017;123:4158–4167. © 2017 American Cancer Society.
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
BACKGROUND: The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer.METHODS: The National Cancer Data Base was queried for unresected patients who received chemotherapy for nonmetastatic pancreatic adenocarcinoma between 2004 and 2012. Four treatment groups were identified: chemotherapy alone, chemotherapy combined with external‐beam radiotherapy (EBRT), chemotherapy combined with intensity‐modulated radiotherapy (IMRT), and chemotherapy combined with SBRT. Propensity score models predicting the odds of receiving SBRT were created to control for potential selection bias, and patients were matched by propensity scores. The survival analysis was performed with the Kaplan‐Meier method.RESULTS: A total of 14,331 patients met the inclusion criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy along with EBRT, IMRT, and SBRT, respectively. The unadjusted median survival before matching was 9.9, 10.9, 12.0, and 13.9 months for patients treated with chemotherapy, EBRT, IMRT, and SBRT, respectively. In separate matched analyses, SBRT remained superior to chemotherapy alone (log‐rank P < .0001) and EBRT (log‐rank P = .0180). After matching, survival did not differ between patients receiving IMRT and patients receiving SBRT (log‐rank P = .0492).CONCLUSIONS: SBRT is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional EBRT. These results support the idea that SBRT is a promising treatment approach for patients with unresected pancreatic cancer. Cancer 2017;123:4158–4167. © 2017 American Cancer Society.
- 1 June 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 224 (6) , 1057-1064
National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors
New guidelines recommend differentiating between carcinoid and pancreatic neuroendocrine tumors (PNETs) during clinical trials. However, little is known about the behavior and incidence of primary pancreatic carcinoid tumors. We performed a retrospective cohort study using the National Cancer Data Base (NCDB) to identify adults with primary PNETs diagnosed between 2004 and 2013. The Kaplan-Meier method was used to evaluate overall survival, and multivariate Cox proportional hazards model was used to assess the hazard of death in resected patients. Of 10,752 patients, 12.7% were diagnosed with carcinoid tumors, 84.7% with nonfunctional and 2.6% with functional PNETs. Although the number of functional PNETs has remained relatively constant over time, rates of nonfunctional and carcinoid tumors have risen dramatically. Only 36 (5.7%) carcinoid tumors were diagnosed in 2004; this increased to 497 (27.7%) in 2013. Overall survival was significantly longer for carcinoid compared with functional and nonfunctional tumors (log-rank p < 0.0001), with 5-year survival rates of 63.1%, 58.3%, and 52.6%, respectively. For patients having resection, overall survival further improved for carcinoid tumors relative to functional (log-rank p = 0.0011) and nonfunctional (log-rank p < 0.0001) tumors, but the survival difference between functional and nonfunctional tumors disappeared (log-rank p = 0.4579); 5-year survival rates were 89.2%, 76.6%, and 78.7%, respectively. On multivariate Cox regression of the resected cohort, mortality was significantly higher for patients with functional (hazard ratio [HR] 1.81) and nonfunctional (HR 1.40) PNETs compared with carcinoid tumors. Primary pancreatic carcinoid tumors are increasingly being diagnosed. Differentiating PNET subtypes plays an important role in prognostication. Resection remains a critical component of care.
- 1 June 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 224 (6) , 1057-1064
National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors
New guidelines recommend differentiating between carcinoid and pancreatic neuroendocrine tumors (PNETs) during clinical trials. However, little is known about the behavior and incidence of primary pancreatic carcinoid tumors. We performed a retrospective cohort study using the National Cancer Data Base (NCDB) to identify adults with primary PNETs diagnosed between 2004 and 2013. The Kaplan-Meier method was used to evaluate overall survival, and multivariate Cox proportional hazards model was used to assess the hazard of death in resected patients. Of 10,752 patients, 12.7% were diagnosed with carcinoid tumors, 84.7% with nonfunctional and 2.6% with functional PNETs. Although the number of functional PNETs has remained relatively constant over time, rates of nonfunctional and carcinoid tumors have risen dramatically. Only 36 (5.7%) carcinoid tumors were diagnosed in 2004; this increased to 497 (27.7%) in 2013. Overall survival was significantly longer for carcinoid compared with functional and nonfunctional tumors (log-rank p < 0.0001), with 5-year survival rates of 63.1%, 58.3%, and 52.6%, respectively. For patients having resection, overall survival further improved for carcinoid tumors relative to functional (log-rank p = 0.0011) and nonfunctional (log-rank p < 0.0001) tumors, but the survival difference between functional and nonfunctional tumors disappeared (log-rank p = 0.4579); 5-year survival rates were 89.2%, 76.6%, and 78.7%, respectively. On multivariate Cox regression of the resected cohort, mortality was significantly higher for patients with functional (hazard ratio [HR] 1.81) and nonfunctional (HR 1.40) PNETs compared with carcinoid tumors. Primary pancreatic carcinoid tumors are increasingly being diagnosed. Differentiating PNET subtypes plays an important role in prognostication. Resection remains a critical component of care.